19 June 2013
Keywords: vertex, initiates, ph, ii, trial, vx-950, hep
Article | 12 December 2005
USA-based Vertex Pharmaceuticals has announced the initiation of a Phase II clinical trial for VX-950, an investigational oral hepatitis C ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 December 2005
18 June 2013
© 2013 thepharmaletter.com